125 related articles for article (PubMed ID: 30959058)
1. Pharmacokinetics and Tolerability of a Novel 17β-Estradiol and Progesterone Intravaginal Ring in Sheep.
Weiss H; Martell B; Constantine GD; Davis SM; Vidal JD; Mayer PR; Doorbar M; Friend DR
J Pharm Sci; 2019 Aug; 108(8):2677-2684. PubMed ID: 30959058
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and tolerability of a novel progesterone intravaginal ring in sheep.
Weiss H; Martell B; Constantine GD; Davis SM; Vidal JD; Mayer PR; Doorbar M; Friend DR
Drug Deliv Transl Res; 2019 Oct; 9(5):1008-1016. PubMed ID: 31066007
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of 28-day estradiol and progesterone vaginal rings in a phase 1 clinical pharmacokinetic study.
Hull L; Stuckey BGA; Hartman K; Zack N; Friend DR
Menopause; 2023 Apr; 30(4):427-436. PubMed ID: 36727806
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the effects of pretreatment with Veramix sponge (medroxyprogesterone acetate) or CIDR (natural progesterone) in combination with an injection of estradiol-17β on ovarian activity, endocrine profiles, and embryo yields in cyclic ewes superovulated in the multiple-dose Folltropin-V (porcine FSH) regimen.
Bartlewski PM; Seaton P; Szpila P; Oliveira ME; Murawski M; Schwarz T; Kridli RT; Zieba DA
Theriogenology; 2015 Oct; 84(7):1225-37. PubMed ID: 26231309
[TBL] [Abstract][Full Text] [Related]
5. Safety and acceptability of intravaginal rings releasing estradiol and progesterone.
Hull ML; Stuckey B; Hartman K; Zack N; Thurman A; Friend DR
Climacteric; 2023 Oct; 26(5):465-471. PubMed ID: 37054722
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, pharmacodynamics, safety and tolerability of an intravaginal ring releasing anastrozole and levonorgestrel in healthy premenopausal women: a Phase 1 randomized controlled trial.
Schultze-Mosgau MH; Waellnitz K; Nave R; Klein S; Kraetzschmar J; Rautenberg T; Schmitz H; Rohde B
Hum Reprod; 2016 Aug; 31(8):1713-22. PubMed ID: 27390369
[TBL] [Abstract][Full Text] [Related]
7. Characterization of anastrozole effects, delivered by an intravaginal ring in cynomolgus monkeys.
Rotgeri A; Korolainen H; Sundholm O; Schmitz H; Fuhrmann U; Prelle K; Sacher F
Hum Reprod; 2015 Feb; 30(2):308-14. PubMed ID: 25432919
[TBL] [Abstract][Full Text] [Related]
8. A phase 1/2, open-label, parallel group study to evaluate the safety and pharmacokinetics of DARE-HRT1 (80 μg estradiol/4 mg progesterone and 160 μg estradiol/8 mg progesterone intravaginal rings) over 12 weeks in healthy postmenopausal women.
Thurman A; Hull ML; Stuckey B; Hatheway J; Zack N; Mauck C; Friend D
Menopause; 2023 Aug; 30(8):817-823. PubMed ID: 37339390
[TBL] [Abstract][Full Text] [Related]
9. Intravaginal impedance and sexual behavior of ovariectomized goats given estrogen alone or in combination with progesterone.
Imwalle DB; Lehrer AR; Katz LS
J Anim Sci; 2007 Aug; 85(8):1908-13. PubMed ID: 17504954
[TBL] [Abstract][Full Text] [Related]
10. Progesterone bioavailability with a progesterone-releasing silicone vaginal ring in IVF candidates.
Dragonas C; Maltaris T; Binder H; Kat M; Mueller A; Cupisti S; Hoffmann I; Beckmann MW; Dittrich R
Eur J Med Res; 2007 Jun; 12(6):264-7. PubMed ID: 17666316
[TBL] [Abstract][Full Text] [Related]
11. Minimized estradiol absorption with ultra-low-dose 10 microg 17beta-estradiol vaginal tablets.
Eugster-Hausmann M; Waitzinger J; Lehnick D
Climacteric; 2010 Jun; 13(3):219-27. PubMed ID: 20423242
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of continuous once-a-week combination 17β-Estradiol/Low- or high-dose levonorgestrel transdermal delivery systems in postmenopausal women.
Karara AH; Harrison LI; Melikian AP; Poola N; Morrison D; Bourg D; Bourg L; Zurth C
J Clin Pharmacol; 2014 May; 54(5):520-7. PubMed ID: 24474034
[TBL] [Abstract][Full Text] [Related]
13. Radioimmunoassay of serum medroxyprogesterone acetate (Provera) in women following oral and intravaginal administration.
Hiroi M; Stanczyk FZ; Goebelsmann U; Brenner PF; Lumkin ME; Mishell DR
Steroids; 1975 Sep; 26(3):373-86. PubMed ID: 1198624
[TBL] [Abstract][Full Text] [Related]
14. Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial.
Vincent KL; Moss JA; Marzinke MA; Hendrix CW; Anton PA; Pyles RB; Guthrie KM; Dawson L; Olive TJ; Butkyavichene I; Churchman SA; Cortez JM; Fanter R; Gunawardana M; Miller CS; Yang F; Rosen RK; Vargas SE; Baum MM
PLoS Med; 2018 Sep; 15(9):e1002655. PubMed ID: 30265679
[TBL] [Abstract][Full Text] [Related]
15. The optimization of an intravaginal ring releasing progesterone using a mathematical model.
Helbling IM; Ibarra JC; Luna JA
Pharm Res; 2014 Mar; 31(3):795-808. PubMed ID: 24135933
[TBL] [Abstract][Full Text] [Related]
16. Parallel assessment of the impact of different hormone replacement therapies on breast density by radiologist- and computer-based analyses of mammograms.
Pettersen PC; Raundahl J; Loog M; Nielsen M; Tankó LB; Christiansen C
Climacteric; 2008 Apr; 11(2):135-43. PubMed ID: 18365856
[TBL] [Abstract][Full Text] [Related]
17. The effect of transdermal and vaginal estrogen therapy on markers of postmenopausal estrogen status.
Gupta P; Ozel B; Stanczyk FZ; Felix JC; Mishell DR
Menopause; 2008; 15(1):94-7. PubMed ID: 17882008
[TBL] [Abstract][Full Text] [Related]
18. Development of polyether urethane intravaginal rings for the sustained delivery of hydroxychloroquine.
Chen Y; Traore YL; Li A; Fowke KR; Ho EA
Drug Des Devel Ther; 2014; 8():1801-15. PubMed ID: 25336923
[TBL] [Abstract][Full Text] [Related]
19. Design of an intravaginal ring for the controlled delivery of 17 beta-estradiol as its 3-acetate ester.
Woolfson AD; Elliott GR; Gilligan CA; Passmore CM
J Control Release; 1999 Sep; 61(3):319-28. PubMed ID: 10477804
[TBL] [Abstract][Full Text] [Related]
20. A phase 1/2, open-label, parallel group study to evaluate the preliminary efficacy and usability DARE-HRT1 (80 μg estradiol/4 mg progesterone and 160 μg estradiol/8 mg progesterone intravaginal RinGSM) over 12 weeks in healthy postmenopausal women.
Thurman A; Hull ML; Stuckey B; Hatheway J; Zack N; Mauck C; Friend D
Menopause; 2023 Sep; 30(9):940-946. PubMed ID: 37625088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
